Last updated: April 24, 2026
Who supplies Cleocin (clindamycin) to the market?
Cleocin is a brand of clindamycin (typically clindamycin hydrochloride) used for bacterial infections. In practice, “suppliers” split into two buckets: (1) original-brand manufacturers and (2) generic manufacturers supplying clindamycin products under abbreviated approvals.
Because “Cleocin” products span multiple dosage forms (most commonly capsules and injectable), the supplier list differs by strength and form. Without a specified strength and dosage form, the supplier base cannot be stated completely and accurately.
Which manufacturers are tied to clindamycin brand supply?
The original brand historically has been sourced by the company that held the brand line for Cleocin (clindamycin). Today, market supply is heavily dominated by generic clindamycin manufacturers, which distribute through wholesalers under NDCs tied to specific dosage forms.
Which generic manufacturers supply clindamycin (typical market pattern)?
Generic clindamycin supply is produced by multiple qualified manufacturers that compete by NDC. Supplier identification is NDC-specific and varies over time based on:
- dosage form (capsule vs injection vs topical products in some markets)
- strength (e.g., 150 mg, 300 mg capsules)
- pack size and labeler
- sourcing changes by distributor and re-packager
What do “supplier” identifiers mean in pharmaceutical sourcing?
For procurement, supplier selection is usually anchored to one of these fields:
- Labeler / NDA holder / ANDA applicant (manufacturer of record for the NDC)
- NDC-specific manufacturer (site) (some labelers use contract manufacturing)
- Wholesaler or distributor (who sells into hospitals and pharmacies)
- GPO/Vendor (institutional contracting layer)
A complete supplier map requires an NDC-level approach, not just the brand name “Cleocin.”
Supplier landscape: what is reliably actionable
A procurement-ready supplier strategy for Cleocin requires:
- NDC-level identification for the exact Cleocin product (dose form and strength).
- ANDAs tied to that NDC to identify the ANDA applicant/labeler.
- Manufacturing site coverage to track continuity and supply risk.
- Distributor coverage by region for availability.
Without those product identifiers, any named list of suppliers would omit parts of the market and risk misalignment with the exact product being purchased.
Key Takeaways
- Cleocin supplier coverage depends on dosage form and strength because clindamycin supply is NDC-specific.
- “Suppliers for Cleocin” in procurement terms means NDC labeler/manufacturer of record for the specific dosage form, not just generic “clindamycin manufacturers.”
- A correct supplier list must be built from NDC-to-ANDA/labeler mapping, then validated by manufacturing site and distributor channel.
FAQs
-
Is Cleocin supplied mainly by the original brand company or generics?
Market supply is predominantly generic for most clindamycin dosage forms.
-
Do clindamycin suppliers stay the same across capsule and injection?
No. Supplier and manufacturer-of-record often differ by dosage form and strength, even when the active ingredient is the same.
-
What is the right unit for supplier selection: brand name or NDC?
NDC is the right unit for supplier selection because labelers and manufacturing sites attach to NDCs.
-
Can a wholesaler be treated as the manufacturer supplier?
No. Wholesalers are distribution channels. The supplier for regulatory and quality purposes is the NDC labeler/manufacturer of record.
-
How do procurement teams manage continuity of supply for clindamycin?
They maintain a multi-NDC, multi-manufacturer coverage model tied to ANDAs and manufacturing sites, then map distribution via local vendors.
References
[1] U.S. Food and Drug Administration. “Drug Registration and Listing System (DRLS).” FDA. https://www.accessdata.fda.gov/scripts/cder/drls/ (accessed 2026-04-24).
[2] U.S. FDA. “Drugs@FDA.” FDA. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-04-24).
